The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

被引：16

作者：

Forsberg, Matthew H. ^{[1
]}

Das, Amritava ^{[2
,3
]}

Saha, Krishanu ^{[2
,4
,5
]}

Capitini, Christian M. ^{[1
,6
]}

机构：

[1] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA

[2] Univ Wisconsin, Wisconsin Inst Discovery, Madison, WI USA

[3] Univ Wisconsin, Morgridge Inst Res, Madison, WI USA

[4] Univ Wisconsin, Dept Med Hist & Bioeth, Madison, WI USA

[5] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA

[6] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI USA

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2018年 / 14卷

关键词：

CAR T-cells; tisagenlecleucel; acute lymphoblastic leukemia; CD19; cancer immunotherapy; chimeric antigen receptor; ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; CHIMERIC ANTIGEN RECEPTORS; BONE-MARROW; TUMOR; CHILDREN; 4-1BB; CD28; CD19; ACTIVATION;

D O I：

10.2147/TCRM.S146309

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Recent advancements in immuno-oncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy.

引用

页码：1573 / 1584

页数：12

共 77 条

[1] Autologous lymphapheresis for the production of chimeric antigen receptor T cells
Allen, Elizabeth S.
Stroncek, David F.
Ren, Jiaqiang
Eder, F.
West, Kamille A.
Fry, Terry J.
Lee, Daniel W.
Mackall, Crystal L.
Conry-Cantilena, Cathy
[J]. TRANSFUSION, 2017, 57 (05) : 1133 - 1141
[2] Novel agents for the treatment of childhood acute leukemia
Annesley, Colleen E.
Brown, Patrick
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (02) : 61 - 79
[3] [Anonymous], FORMAL REQUEST NATL
[4] [Anonymous], BLOOD S1
[5] [Anonymous], BLOOD S1
[6] [Anonymous], 2015, BLOOD, DOI DOI 10.1182/BLOOD.V126.23.684.684
[7] Bone-marrow relapse in paediatric acute lymphoblastic leukaemia
Bailey, L. Charles
Lange, Beverly J.
Rheingold, Susan R.
Bunin, Nancy J.
[J]. LANCET ONCOLOGY, 2008, 9 (09) : 873 - 883
[8] Barlas Stephen, 2014, P T, V39, P563
[9] Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
Brentjens, Renier J.
Santos, Elmer
Nikhamin, Yan
Yeh, Raymond
Matsushita, Maiko
La Perle, Krista
Quintas-Cardama, Alfonso
Larson, Steven M.
Sadelain, Michel
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5426 - 5435
[10] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Brentjens, Renier J.
Riviere, Isabelle
Park, Jae H.
Davila, Marco L.
Wang, Xiuyan
Stefanski, Jolanta
Taylor, Clare
Yeh, Raymond
Bartido, Shirley
Borquez-Ojeda, Oriana
Olszewska, Malgorzata
Bernal, Yvette
Pegram, Hollie
Przybylowski, Mark
Hollyman, Daniel
Usachenko, Yelena
Pirraglia, Domenick
Hosey, James
Santos, Elmer
Halton, Elizabeth
Maslak, Peter
Scheinberg, David
Jurcic, Joseph
Heaney, Mark
Heller, Glenn
Frattini, Mark
Sadelain, Michel
[J]. BLOOD, 2011, 118 (18) : 4817 - 4828

← 1 2 3 4 5 6 7 8 →